Creative Biolabs Expands AI-Powered Antibody Design Solutions

New AI models accelerate development of sdAb, ADC, and multi-specific antibodies

Published on Feb. 17, 2026

Got story updates? Submit your updates here. ›

Creative Biolabs, a global leader in biotechnology and antibody engineering, has announced a significant expansion of its Artificial Intelligence (AI) division. By integrating advanced deep generative models and structural prediction tools like AlphaFold, the company is tackling persistent bottlenecks in drug development, including long R&D cycles and high lead attrition rates.

Why it matters

Creative Biolabs' AI-driven approach addresses the common challenge of traditional antibody discovery yielding potent binders that fail in late-stage development due to poor solubility or immunogenicity. The company's proprietary developability scoring engine optimizes both binding affinity and developability, delivering lead candidates in months instead of years.

The details

Creative Biolabs' AI-powered solutions include services for single domain antibody (sdAb) design, antibody-drug conjugate (ADC) design, and multi-specific antibody design. These platforms leverage AI to target cryptic epitopes, model complex antibody-linker-payload interactions, and ensure precise 3D structural alignment for engaging multiple targets simultaneously. Every AI-generated design undergoes rigorous wet lab validation, representing the 'gold standard' of modern biologics development according to industry experts.

  • Creative Biolabs announced the expansion of its AI division on February 16, 2026.

The players

Creative Biolabs

A global leader in biotechnology and antibody engineering that provides end-to-end solutions for biopharmaceutical discovery.

AlphaFold

An advanced deep learning model developed by DeepMind that can accurately predict the 3D structure of proteins.

Got photos? Submit your photos here. ›

What’s next

Creative Biolabs plans to continue expanding its AI-powered capabilities to further accelerate the development of innovative biotherapeutics.

The takeaway

By leveraging advanced AI models and structural prediction tools, Creative Biolabs is revolutionizing the antibody design process, delivering lead candidates faster and with improved developability, which could significantly impact the future of biopharmaceutical discovery.